Kempharm Inc., of Coralville, Iowa, reported data from an oral human abuse liability, pharmacokinetic and safety study of KP201/APAP at the American Academy of Pain Medicine meeting in Palm Springs, Calif., showing that KP201/APAP was associated with lower exposure to hydrocodone at the eight- and 12-tablet doses compared to Norco (hydrocodone bitartrate/APAP), while exposure at the low-dose (four tablets) was bioequivalent.